Stellar Biotechnologies Announces Results of KLH Preclinical Study

Stellar Biotechnologies Inc. (TSXV:KLH, OTCQB:SBOTF) announced the presentation of findings from the Keyhole Limpet Hemocyanin (KLH) preclinical study, which they conducted with a partner, showing that the sources and molecule form can affect the consistency and degree of antibody response to KLH.

As quoted in the press release:

In the study, anti-KLH IgM and IgG responses were measured in rats immunized with five different KLHs from three KLH commercial sources, including Stellar KLH. All test articles were administered without co-injection of an adjuvant. Dose analysis and biophysical characterization were also conducted. Among GMP grade KLHs tested in the study, Stellar HMW KLH and Stellar Subunit KLH elicited the greatest IgM and IgG responses. In addition, Stellar Subunit KLH elicited the greatest IgM and IgG responses compared to the subunit KLHs from other sources.

Click here to read the full Stellar Biotechnologies Inc. (TSXV:KLH, OTCQB:SBOTF) press release.